|
|
|
Volumn 23, Issue 4, 1996, Pages 475-493
|
|
Adjuvant drug therapy for operable breast cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARMUSTINE;
CHLORMETHINE;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
EPIRUBICIN;
ESTROGEN RECEPTOR;
ETOPOSIDE;
FLUOROURACIL;
FLUOXYMESTERONE;
GRANULOCYTE COLONY STIMULATING FACTOR;
METHOTREXATE;
MONOCLONAL ANTIBODY;
NAVELBINE;
PACLITAXEL;
PREDNISONE;
PROCARBAZINE;
TAMOXIFEN;
THIOTEPA;
VINBLASTINE;
VINCRISTINE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER RECURRENCE;
CANCER REGRESSION;
CLINICAL TRIAL;
DRUG MEGADOSE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
META ANALYSIS;
ORAL DRUG ADMINISTRATION;
OVARIECTOMY;
PRIORITY JOURNAL;
RECURRENCE RISK;
REVIEW;
RISK ASSESSMENT;
AGE DISTRIBUTION;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
COMBINED MODALITY THERAPY;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FEMALE;
FLUOROURACIL;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
METHOTREXATE;
NEOPLASM RECURRENCE, LOCAL;
RADIOTHERAPY, ADJUVANT;
RISK ASSESSMENT;
TAMOXIFEN;
|
|
EID: 0029799940
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (27)
|
|
References (0)
|
